Canlubo, Baby Boy .
HRN: 26-97-93 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/19/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
07/19/2025
07/25/2025
IV
42mg
IV
PSNB
Waiting Final Action
Indication: Empiric Type of Infection: Unspecified Sepsis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes